Serotonin 5-HT<sub>1A</sub> receptor binding in people with panic disorder: positron emission tomography study

Jon R. Nash,* Peter A. Sargent,* Eugenii A. Rabiner, Sean D. Hood, Spiillos V. Argyropoulos, John P. Potokar, Paul M. Grasby and David J. Nutt

Background
The importance of the neurotransmitter serotonin (5-HT) in the pathophysiology of anxiety is well known. A key role for postsynaptic 5-HT<sub>1A</sub> receptors has recently been suggested in studies of genetic knockout mice.

Aims
To measure 5-HT<sub>1A</sub> receptor binding in patients with panic disorder in the untreated state and after recovery on treatment with selective serotonin reuptake inhibitors (SSRIs).

Method
Nine asymptomatic untreated patients with panic disorder, seven patients recovered on SSRI medication and nineteen healthy volunteers underwent a single positron emission tomography (PET) scan using the 5-HT<sub>1A</sub> tracer [11C]WAY-100635.

Results
In comparison with controls, both presynaptic and postsynaptic 5-HT<sub>1A</sub> receptor binding was reduced in untreated patients, with the most significant reductions being in the raphe, orbitofrontal cortex, temporal cortex and amygdala. In recovered patients presynaptic binding was reduced, but there was no significant reduction in postsynaptic binding.

Conclusions
Panic disorder is associated with reduced 5-HT<sub>1A</sub> receptor availability, which is also known to have a key role in depression.

Declaration of interest
Pump priming for the study was provided by a small grant from SmithKline Beecham (now GlaxoSmithKline). Funding detailed in Acknowledgements.

The monoamine neurotransmitter serotonin (5-HT) has an important role in both the pathophysiology and treatment of anxiety and panic attacks. The strongest evidence that a specific abnormality of the serotonin system predisposes or contributes to anxiety comes from studies of the 5-HT<sub>1A</sub> receptor. 'Knockout' mice bred without 5-HT<sub>1A</sub> receptors in the cerebral cortex and limbic system show increased anxiety behaviours and patients with panic disorder have been shown by challenge testing to have subsensitivity of these receptors. Furthermore, the azapirone 5-HT<sub>1A</sub> agonist buspirone is licensed for the treatment of generalised anxiety disorder in the UK. In a systematic review of 36 trials of patients treated for generalised anxiety disorder azapirone, including buspirone, were found to be superior to placebo in short-term studies (4–9 weeks).

The development of select radiotracers for the 5-HT<sub>1A</sub> receptor now allows a direct examination of this receptor system postsynaptic 5-HT<sub>1A</sub> receptor binding was reduced in social anxiety disorder. That study compared 12 unmedicated male patients with social anxiety disorder with 18 healthy controls. Six of these patients had comorbid agoraphobia. Six regions of interest were examined a priori – reduction of 5-HT<sub>1A</sub> binding was found in the amygdala, anterior cingulate, insula, medial orbitofrontal cortex and raphe. After Bonferroni correction only the differences in the amygdala and anterior cingulate cortex remained significant. There was no significant correlation between state or trait anxiety scores and regional 5-HT<sub>1A</sub> binding potential in both groups.

In this study, we used the PET tracer [11C]WAY-100635 which allows in vivo quantification of 5-HT<sub>1A</sub> receptors with exquisite delineation and precision. Specifically, we wished to confirm the findings of Neumeister et al who extended the findings to look at more regions of interest and finally examine the effect of SSRI treatment. Our specific hypothesis was that patients with panic disorder would have reductions in 5-HT<sub>1A</sub> receptor binding in anxiety-associated regions of the brain, and that SSRI treatment would not affect 5-HT<sub>1A</sub> receptor availability.

Methods

Recruitment of participants
Nine unmedicated male patients with a primary diagnosis of panic disorder with or without agoraphobia (DSM–IV criteria) were recruited for PET scanning from the out-patient clinic of the Psychopharmacology Unit, Bristol Royal Infirmary. Seven patients were naive to antidepressant therapy and two had taken a tricyclic antidepressant in the past. No patient had been on regular psychotropic medication in the previous 3 months. Exclusion criteria included current or comorbid major depression, serious physical illness, a history of bipolar affective disorder, current or

*These authors contributed equally to the work.
past drug or alcohol dependence, current or previous treatment with mood stabilisers or antipsychotic medication, and current treatment with benzodiazepines. Nineteen healthy age-matched male volunteers were recruited for PET scanning from hospital staff and by advertisement, and acted as the control group. Exclusion criteria for volunteers were a history of psychiatric disorder, including drug or alcohol dependence, or a history of serious physical illness, including neurological disorders.

A further 7 male patients with panic disorder who were established on SSRI treatment were recruited for PET scanning from the same clinic. They had received open-label treatment with paroxetine hydrochloride (Table 1) or sertraline (1 patient: daily dose 50 mg, duration of treatment 24 months) and remained on treatment at the time of the scan. Clinical response was confirmed by a failure to meet DSM–IV criteria for current panic disorder, and an improvement of at least 2 points on the Clinical Global Impression (CGI) scale12 (much improved). Thus, in addition to the 9 untreated patients with panic disorder, we were able to study a second patient group comprising of 7 recovered patients with panic disorder on SSRI treatment.

All participants were screened for psychiatric disorders by clinical interview and using the Structured Clinical Interview for DSM–IV (SCID–I).13 A screening physical examination was performed and the Hamilton Rating Scale for Anxiety (HRSA)16 was completed. The Beck Depression Inventory (BDI)15 and the Hamilton Rating Scale for Depression (HRSD)14 was completed. The Beck Depression Inventory was acquired in two-dimensional mode for correction of tissue attenuation. All participants then received [11C]WAY-100635 dose 50 mg, duration of treatment 24 months) and remained on treatment with benzodiazepines. Nineteen healthy age-matched male volunteers were recruited for PET scanning from hospital staff and by advertisement, and acted as the control group. Exclusion criteria for volunteers were a history of psychiatric disorder, including drug or alcohol dependence, or a history of serious physical illness, including neurological disorders.

A further 7 male patients with panic disorder who were established on SSRI treatment were recruited for PET scanning from the same clinic. They had received open-label treatment with paroxetine hydrochloride (Table 1) or sertraline (1 patient: daily dose 50 mg, duration of treatment 24 months) and remained on treatment at the time of the scan. Clinical response was confirmed by a failure to meet DSM–IV criteria for current panic disorder, and an improvement of at least 2 points on the Clinical Global Impression (CGI) scale12 (much improved). Thus, in addition to the 9 untreated patients with panic disorder, we were able to study a second patient group comprising of 7 recovered patients with panic disorder on SSRI treatment.

All participants were screened for psychiatric disorders by clinical interview and using the Structured Clinical Interview for DSM–IV (SCID–I).13 A screening physical examination was performed and the Hamilton Rating Scale for Depression (HRSD)15 was completed. The Beck Depression Inventory (BDI)15 and the Hamilton Rating Scale for Anxiety (HRSA)16 were completed 1 h before each scan. All participants gave informed written consent to the study, which was approved by local ethics committees. Permission to administer the radioactive ligand was obtained from the UK Administration of Radioactive Substances Advisory Committee. Agreement to participate in the study was obtained from the general practitioner.

Positron emission tomography scanning was carried out at the Medical Research Council (MRC) Cyclotron Unit, Hammersmith Hospital, London. Participants were accompanied from Bristol by the treating psychiatrist on the day of the scan.

Scanning protocol
Scans were performed on an ECAT 935B PET camera (Control Technology, Inc., Knoxville, Tennessee, USA). This scanner acquires 31 planes of data with an axial field of view (FOV) of 10.3 cm. The scanning method is described in full detail elsewhere.17

[Carbonyl11C]WAY-100635 was prepared at the Cyclotron Unit, MRC Clinical Sciences Centre. A 10 min transmission scan was acquired in two-dimensional mode for correction of tissue attenuation. All participants then received 11C]WAY-100635 injected intravenously over 30 s. Dynamic PET data were acquired in three-dimensional mode for 90 min after injection. The emission data were scatter corrected and reconstructed using a reprojection algorithm.

Kinetic modelling of [11C]WAY-100635
Quantitative tracer kinetic modelling was performed using a reference tissue compartmental model. Cerebellum was used as the reference tissue. The model allows estimation of binding potential and of the relative delivery of radioligand normalised to the cerebellum (Rv). Parametric images of binding potential and Rv were calculated as described elsewhere.10

Regions of interest and statistical analysis
Three groups were defined: untreated patients with panic disorder (n=9), patients treated with SSRI medication (n=7) and controls (n=19). Regions of interest for 21 brain regions were defined using a previously validated database (for the 20 postsynaptic regions) and by hand for the raphe, and regional binding potential values were obtained by applying the regions of interest to the parametric binding-potential images and taking the mean voxel value.18 Statistical analysis of the regional binding potential and Rv data was performed using a single repeated-measures two-way analysis of variance (ANOVA) with Greenehouse–Geisser correction using SPSS version 10.1 for Windows, one factor being group (controls, untreated panic, treated panic) and the other factor being region. Where significant group or group × region interactions were obtained with ANOVA, post hoc t-tests were performed for binding potential values in individual regions of interest. Analysis was also performed separately for a composite of the 20 postsynaptic regions as a measure of global postsynaptic binding. All statistical tests were two-tailed and reported at P<0.05.

Results
Participants
Characteristics of the scanned participants are shown in Table 1. There were no differences between the three groups in terms of age and no differences in illness characteristics (duration of illness, history of agoraphobia or history of previous depression) between the untreated and treated patient groups. Untreated patients had higher anxiety scores than treated patients on the day of the scan but depression scores were not significantly different. The mean dose and duration of SSRI treatment are consistent with standard clinical treatment for panic disorder.2

Region of interest analysis for binding potential
The ANOVA of binding potential values for the three groups found a main effect of group (F=4.15, d.f.=2,32, P=0.025) as expected, a main effect of region (F=81.925, d.f.=20,640, P<0.001) and a region × group interaction (F=2.448, d.f.=40,640, P=0.007).

Post hoc unpaired t-tests found binding potential values to be significantly different for untreated patients v. controls in 17 of 21 regions. The areas with the most significant reductions were the raphe, amygdala, orbitofrontal cortex and anterior lateral temporal cortex (P<0.01). Mean binding potential values were lower in the group of untreated patients with panic disorder, relative to the control group, by 24% in the raphe (P=0.005; Fig. 1) and by 16% in all postsynaptic regions combined (P<0.05; Fig. 2).

In contrast, for treated patients v. controls only 3 of the 21 identified regions were significantly different on post hoc t-testing (raphe, hippocampus and anterior medial temporal cortex at P<0.05). No significant difference was seen in global postsynaptic binding for treated patients v. controls.

For treated v. untreated patients, only one region was significantly different (orbitofrontal cortex). No significant difference was seen in global postsynaptic binding for treated patients v. untreated patients.

Region of interest analysis for Rv
The ANOVA of Rv values for the three groups found no effect of group (F=1.83, d.f.=2,29, P=0.179), but as expected a main effect of region (F=82.3, d.f.=20,580, P<0.001) and a group × region interaction (F=2.03, d.f.=40,580, P=0.02). Post hoc unpaired t-tests found Rv values to be significantly different between the unmedicated patients and controls in one region of interest only (orbitofrontal cortex: P<0.05).
Correlations with clinical variables

There were no significant correlations of binding potentials against a range of clinical variables, including age, anxiety and depression scores, and treatment dose (data not shown).

Discussion

This PET study measured 5-HT_{1A} receptor density in both untreated and recovered patients with panic disorder. It demonstrates major differences in presynaptic raphe 5-HT_{1A} receptor density between controls and patients in both the untreated and recovered states. This study confirms the findings of Neumeister et al., but extends their study to look at more regions of interest and addresses the effect of SSRI treatment in panic disorder. In untreated patients, lower binding was also seen in most postsynaptic regions, most significantly in the ‘anxiety circuit’ of the orbitofrontal cortex, temporal lobe and amygdala. In treated patients, lower binding was also seen in the raphe, but was much less widespread in postsynaptic regions.

Reduced SHT_{1A} binding in panic disorder

Recent evidence has specifically implicated 5-HT_{1A} receptors in the control of anxiety and suggested that reduced function of these receptors may contribute to the development of pathological anxiety.

(a) It has been shown in animal models that the anxiolytic activity of SSRIs is dependent on increased binding of serotonin to postsynaptic 5-HT_{1A} receptors.
and with the model of anxiety postulated from studies of 5-HT1A receptors. The reported subsensitivity to pharmacological challenge in the orbitofrontal cortex and limbic system has revealed that circuits involving the amygdala, temporal cortex and orbitofrontal cortex mediate the perception of threat and the experience of anxiety in humans. Evidence for altered function of gamma-aminobutyric acid and serotoninergic neurotransmission in patients with panic disorder is growing, although a primary aetiological role has yet to be established. Although panic may originate in brainstem structures, recent studies have identified an inhibitory role for specific cortical regions, including the orbitofrontal cortex. A deficit of 5-HT1A receptors, as found in our study, may lead to a relative decrease in the ability of the brain to control panic anxiety.

Interesting comparisons can be drawn between our findings and those from PET studies of 5-HT1A binding in patients with depression. These studies also found lower presynaptic and global postsynaptic 5-HT1A binding in patients compared with controls. This similarity is not unexpected as anxiety and depressive disorders have a clinical overlap, both being brought on by stress-related factors and both responding to SSRI medication. Although there were some differences between the disorders in the postsynaptic regions showing the greatest alterations in binding (orbitofrontal and anterior temporal cortices in panic, anterior cingulate in depression), there is a consistent finding of a general reduction in postsynaptic serotonin receptors.

Our findings in untreated patients also correspond with those of the previously reported study of 5-HT1A receptor binding in patients with untreated panic disorder using [18F]-FCWAY, in which a reduction in binding was found in the anterior cingulate, posterior cingulate and raphe regions. Using a different radiotracer and quantification method, 5-HT1A receptor binding was reduced in two of these three regions in our study. We also found more widespread reductions of 5-HT1A binding; however, further comparison with the Neumeister et al study is restricted as only six regions of interest were reported in total and receptor quantification with this radioligand is problematic in cortical areas owing to the retention of the fluoride signal in adjacent skull bones.

This research finding of reduced 5-HT1A binding has therefore now been replicated in both depression and panic disorder, and has important implications for our understanding of the aetiology of these disorders. Animal studies have shown that 5-HT1A binding can be altered by both genetic and environmental factors, including physical and biological stressors, and that altered 5-HT1A binding is associated with other abnormalities of serotonin function. As neuroimaging techniques allow the replication of these findings in human studies, it becomes possible to create a hypothesis of reduced serotoninergic neurotransmission via 5-HT1A receptors as a biological pathway that can bring together such diverse factors as genetic predisposition, early life trauma, physical illness and stressful life events in the aetiology of anxiety and affective disorders.

**Effect of SSRI treatment on 5-HT1A binding**

There was no difference in global postsynaptic binding between recovered patients on SSRI medication and controls, and binding was significantly lower in only two of the forebrain regions and the raphe compared with controls. In animal studies, Wener et al and Li et al found reduced 5-HT1A binding in the midbrain following chronic fluoxetine administration. However, other animal studies have found no effects of SSRIs on [3H]8-OH-DPAT binding in any brain region. The smaller differences from controls in postsynaptic binding in the SSRI-treated group compared with the untreated group may be due to a lack of power to detect a difference between SSRI-treated patients (n=7) and controls.
The mean binding potential values for this group were inter-
mediate between those of the unmedicated patients with panic
disorder and the healthy controls. Larger numbers of
participants may have clarified whether the binding potential
values for these patients does indeed lie between the untreated
patients and controls.

An alternative explanation is that SSRI treatment of panic
disorder may be associated with ‘normalisation’ of 5-HT1A
binding. This is possibly not a direct effect of SSRI treatment,
as treatment was not associated with altered binding in our study
of patients with depression, although SSRI treatment in this study
was of a shorter duration and at a lower dose.17

Our finding in untreated patients with panic disorder of
reduced raphe and postsynaptic 5-HT1A binding may be related
to the chronic stress associated with, and possibly causal of,
anxiety. Stress has been shown in animals to reduce 5-HT1A
receptor density and function and, via overstimulation of
glucocorticoid receptors, also leads to a loss of dendritic spines
in neurons.40 Interestingly, although previous studies had not
found a correlation between cortisol levels and 5-HT1A expression
in patients with depression,31 a strongly negative correlation was
recently reported between hippocampal 5-HT1A expression and
cortisol levels in social anxiety disorder.41 A ‘normalisation’
of postsynaptic 5-HT1A binding with treatment could therefore
be explained by a reduction in stress associated with recovery.

Anxiety and depressive disorders are frequently coexisting
conditions and have many clinical similarities, including sleep
disturbance, fatigue, reduced concentration and irritability. Both
respond to treatment with serotoninergic antidepressants, which
suggests a commonality in underlying pathophysiology. Our
imaging data suggest that both disorders share at least one
neurochemical pathophysiological feature, namely reduced
5-HT1A receptor binding. Our findings are also consistent with preclinical
and clinical studies of anxiety, including the findings that reduced
5-HT1A receptor binding is causal of anxiety-like behaviours in
5-HT1A knockout mice,24 and that patients with panic disorder
have impaired 5-HT1A receptor function in neuroendocrine challenge
tests.4

The numbers of individuals participating in this study are low,
but not untypical for PET studies of this kind. None the less,
significant reductions in binding potential values were still found
in 17 out of 21 brain regions in unmedicated patients with panic
disorder compared with healthy controls. On the other hand,
reductions in binding potential were only found in 3 out of the 21
regions in the SSRI-treated patients. Less confidence can be
placed in the latter finding.

It would be of considerable interest to see whether similar
changes in binding potential occur in female patients with panic
disorder as the prevalence of this condition is about twice as high
in women as in men.

Positron emission tomography is a highly sensitive procedure
and it is important to consider sources of bias in the methodology.
Our study did not include estimations of brain volume, partly
because the magnetic resonance imaging scanner encloses the
patient to an extent that most patients with untreated panic
disorder would find too frightening. It seems reasonable to
proceed without these measurements as there is no evidence from
other studies that panic disorder is associated with reduced brain
volume.21 Although the PET scanner is less oppressive than
magnetic resonance imaging, our untreated patients were
significantly more anxious than controls prior to the scan and
subjectively found the scanning procedure more anxiogenic than
those in the treated and control groups. This could in theory have
contributed to the differences seen, although our evidence
suggests that acute physiological alterations of serotonin in
humans do not significantly affect cortical WAY-100635 binding,18
and evidence from animal studies suggests that acute stress does
not lead to a significant reduction in 5-HT1A binding.42 Variations
in cerebral blood flow of the magnitude expected between anxious
patients and controls are unlikely to affect the [11C]-WAY100635
signal.19 Finally, it has previously been shown that 5-HT1A binding
reduces with age, and although the age differences between groups
were not significant, our findings of reduced binding were in the
group with the younger mean age.

In part because of the cost of PET studies and the logistical
problems involved in scanning individuals, participant numbers
in PET studies tend to be low and replication of results is therefore
acknowledged to be very important in the field. Thus, our study
is important as it confirms the findings of Neumeister et al.49
extends these to look at more regions of interest and examines the effect
of SSRI treatment.

Clinical implications
Positron emission tomography demonstrates that patients with
untreated panic disorder have lower 5-HT1A receptor binding compared with controls. This finding is consistent with predic-
tions from animal models of anxiety. This reduction in binding
is especially significant in the orbitofrontal cortex, temporal lobes
and amygdala – these regions are known to control anxiety
responses and reduced 5-HT1A binding in these areas may be a
biological factor that confers vulnerability to anxiety disorders.

Our imaging data shows that reduced 5-HT1A binding is a
pathophysiological feature of both panic disorder and depression,
and may represent a common neurobiological pathway in the
development of these stress-related disorders.

Limitations
The observations of the effects of SSRI treatment would have been
more powerful if patients had been scanned before and after
 treatment. In addition, owing to the use of ionising radiation, only
male patients were included in the study.

Jon R. Nash, MRCPsych, MRCPsych, Pharmacology Unit, University of Bristol,
Peter A. Sargent, MD, MRCPsych, Gofordsire and Buckinghamshire Mental Health
Foundation Trust; Eugenii A. Rabiner, FCPSych, Medical Research Council
Cyclotron Unit, Hammersmith Hospital, London; Sean D. Hood, MSc, FRANZCP
Spiliou V. Argyropoulos, PhD, MRCPsych; John P. Petkova, MD, MRCPsych,
Pharmacology Unit, University of Bristol; Paul M. Grasby, MD, FRCP, MRCPsych,
Medical Research Council Cyclotron Unit, Hammersmith Hospital, London;
David J. Nutt, DM, FRCP, FRCPsych, FMedSci, Pharmacology Unit, University of
Bristol, UK
Correspondence: Professor David Nutt, Psychopharmacology Unit, University
of Bristol, Dorothy Hodgkins Building, Whitson Street, Bristol BS8 1NY, UK.
Email: David.J.Nutt@bristol.ac.uk
First received 4 Jun 2007, final revision 26 Feb 2008, accepted 18 Apr 2008

Acknowledgements
This study was initiated by a grant from SmithKline Beecham, and the scanning costs were
covered by a program grant to P.M.G. from the MRC. These data were presented in poster
form at the British Association for Psychopharmacology Summer Meeting (20–23 July 2003,
Cambridge, UK) and the annual European College of Neuropsychopharmacology Congress

References
2 Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR,
den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. Evidence-based
guidelines for the pharmacological treatment of anxiety disorders:
recommendations from the British Association for Psychopharmacology. J
3 Parks CL, Robinson PS, Siblee E, Shenk T, Toth M. Increased anxiety of mice
4 Lesch KP, Wiesmann M, Holt A, Muller T, Desselkamp-Tietze I, Oesterheder M,
Schulte HM. 5-HT1A receptor-efferent system responsivity in panic disorder.
5 Chessick CA, Allen MH, Thase M, Battista Miralda da Cunha AB, Kapczinski
FF, de Lima MS, dos Santos Souza U. Azapirones for generalized anxiety
6 Neumeister A, Baine E, Nugent AC, Carson BR, Bonne O, Luckenbaugh DA,
Eckelmann W, Herschovitch P, Chaney DS, Drewevs WC. Reduced serotonin
7 Carson RE, Wu Y, Landl M, Ma Y, Der MG, Herschovitch P, Eckelmann WC. Brain
uptake of the acid metabolites of F-18-labelled WAY100635 analogs. J Cereb
8 Lannenberger RR, Mutterhauser M, Spindelegger C, Wadsak W, Klein N, Mien
LK, Holik A, Attarbaschi T, Massaheb N, Sachier J, Geiss-Granadia T, Kletter K,
Kasper S, Taubacher J. Reduced serotonin-1A receptor binding in social
9 Pike VW, McCarron JA, Lammertsma AA, Osman S, Hume SP, Sargent PA,
Bench CJ, Cliff IE, Fletcher A, Grasby PM. Exquisite delineation of 5-HT1A
receptors in human brain with PET and [carbonyl-11C]WAY100635. Eur J
10 Gunn RN, Sargent PA, Bench CJ, Rabiner EA, Osman S, Pike VW, Hume SP,
Grasby PM, Lammertsma AA. Trajectory kinetic modeling of the 5-HT1A
11 American Psychiatric Association. Diagnostic and Statistical Manual of
12 Gay W. ECDEU Assessment Manual for Psychopharmacology. US Department
of Mental Health, 1976: 179–222.
13 First MB, Spitzer RL, Williams J. Structural Clinical Interview for
York State Psychiatric Institute, Biometrics Research, 1997.
14 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry
15 Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for
1959; 32: 50–5.
17 Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Mesa C, Meyer J, Gunn RN,
18 Rabiner EA, Messa C, Sargent PA, Husted-Kjaer K, Montgomery A, Lawrence
binding to 5-HT1A receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and
19 Rosen JB, Schulkin J. From normal fear to pathological anxiety. Psychol Rev
37: 2–8.
21 Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of
DJ. Does 5-HT re-strain panic? A tryptophan depletion study in panic disorder
23 Argypolou SV, Hood SD, Adrovor M, Bell CJ, Rich AS, Nash JR, Rich NC,
Witlock M. Tryptophan depletion reverses the therapeutic effect of selective
25 Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of
26 Malizia AL. Brain imaging and anxiety disorders. In Anxiety Disorders (eds
27 Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased
brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary
28 Moron E, Kulikka JT, Shlik J, Vasaar V, Vanninen E, Tihonen J. Reduced brain
serotonin transporter binding in patients with panic disorder. Psychiatrie Res
29 Bailey JE, Argypolou SV, Lightman SL, Nutt DJ. Does the brain
noradrenaline network mediate the effects of the CD2 challenge? J
30 Kent JM, Coplan JD, Mawlawi O, Martinez JM, Browne ST, Silfstein M,
Martinez D, Abi-Dargham A, Lannele M, Gorman JM. Prediction of panic
response to a respiratory stimulant by reduced orbitofrontal cerebral blood
31 Drewevs WC, Frank E, Price JC, Kuper DJ, Greer PJ, Mathis C. Serotonin type-
32 McKttrick CR, Blanchard DC, Blanchard RJ, McEwen BS, Sakai RK. Serotonin
transporter binding in a colony model of chronic social stress. Biol Psychiatry
33 Ase AR, Reader TA, Hen R, Riad M, Descaries L. Regional changes in density
of serotonin transporter in the brain of 5-HT1A and 5-HT1B knockout mice, and
34 Welsh SR, De Montigny C, Desroches J, Desjardins P, Suranyi-Cadotte BE.
 Autoradiographic quantification of serotonin1A receptors in rat brain
35 Li Q, Brownfield MS, Levy AD, Battaglia G, Cabrera TM, Van de Kar LD.
 Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by long-
term treatment with fluoxetine, but not desipramine, in male rats. Biol
Psychiatry 1996; 34: 300–8.
36 Hensler JG, Kovachich GB, Frazer A. A quantitative autoradiographic study of
serotonin1A receptor regulation: effect of 5,7-dihydroxytryptamine and
37 Le Pool E, Lima L, Laporte AM, Even C, Doucet E, Fattaccini CM, Laaris N,
Hamon M, Lantfumey L. Central serotonin receptors and chronic treatment with
selective serotonin reuptake inhibitors: comparison between fluoxetine and
38 Li Q, Mumma NA, Van de Kar LD. Chronic fluoxetine induces a gradual
desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain
Gn and Gp proteins and in endocrine responses to 5-HT1A agonist. J
Pharmacol Exp Ther 1996; 279: 1035–42.
39 Li Q, Mumma NA, Battaglia G, Van de Kar LD. A desensitization of
hypothalamic 5-HT1A receptors by repeated injections of paroxetine:
reduction in the levels of Gp and Gn proteins and neuroendocrine responses,
but not in the density of 5-HT1A receptors. J Pharmacol Exp Ther 1997; 283:
1581–90.
40 Duman RS. Depression: a case of neuronal life and death? Biol Psychiatry
2004; 56: 140–5.
41 Lannenberger R, Wadsak W, Spindelegger C, Mutterhauser M, Klein N, Mien
LK, Attarbaschi T, Massaheb N, Sachier J, Holik A, Geiss-Granadia T, Kletter K,
Kasper S. Hippocampal serotonin 1A receptor binding correlates with cortisol
plasma levels in social anxiety disorder. Eur Neuropsychopharmacol 2006; 16
(suppl 4): S270.
42 Steciuk M, Kram M, Kramer GL, Petty F. Acute stress does not alter 5-HT1A
receptor density. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24:
155–61.
Serotonin 5-HT$_{1A}$ receptor binding in people with panic disorder: positron emission tomography study
Jon R. Nash, Peter A. Sargent, Eugenii A. Rabiner, Sean D. Hood, Spilios V. Argyropoulos, John P. Potokar, Paul M. Grasby and David J. Nutt
Access the most recent version at DOI: 10.1192/bjp.bp.107.041186

References
This article cites 37 articles, 5 of which you can access for free at: http://bjp.rcpsych.org/content/193/3/229#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at /letters/submit/bjprcpsych;193/3/229

Downloaded from http://bjp.rcpsych.org/ on June 27, 2017
Published by The Royal College of Psychiatrists